

CLAIMS

1. A method for assessing the risk of developing lamotrigine-induced cutaneous adverse drug reaction in a patient, comprising the step of detecting the presence of HLA-A*0207 allele, wherein the presence of HLA-A*0207 allele indicates the patient has a higher risk of developing the lamotrigine induced cutaneous adverse drug reaction compared to a patient without the HLA-A*0207 allele and the cutaneous adverse drug reaction comprises at least one of the following reactions: maculopapular eruption (MPE), fixed drug eruption (FDE), Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) or drug rash with eosinophilia and systemic symptoms (DRESS).
2. The method according to claim 1, further comprising the step of detecting the presence of HLA-B*1502.
3. The method according to claim 2, wherein said HLA-B*1502 or HLA-A*0207 allele is detected in the DNA, RNA, proteins, cells or serum sample prepared from the peripheral blood of the patient.
4. A method of manufacturing a detection reagent to evaluate the risk of developing a cutaneous adverse drug reaction induced by the anti-epileptic drug Lamotrigine, said detection reagent comprises an agent for detecting an HLA-A*0207 allele, wherein the presence of the HLA-A*0207 allele indicates a patient has a higher risk of developing cutaneous adverse drug reaction compared to a subject without the HLA-A*0207 allele and the cutaneous adverse drug reaction comprises at least one of the following reactions: maculopapular eruption (MPE), fixed drug eruption (FDE),

Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) or drug rash with eosinophilia and systemic symptoms (DRESS).

5. The method according to claim 4, wherein the agent comprises an oligonucleotide that specifically hybridizes to the HLA-A*0207 allele.

6. The method according to claim 4, further comprising an agent for detecting the presence of HLA-B*1502 allele.

7. The method e according to claim 6, wherein the agent comprises an oligonucleotide that specifically hybridizes to the HLA-B*1502 allele.